The story, briefly
BioMarin’s filed numbers show a business that has grown revenue by more than half over the past several years and is now absorbing a $4.8 billion acquisition while still growing strongly. The stock trades at a price-to-sales ratio that sits near a decade low, even as the underlying business is arguably stronger than it has ever been. Those two readings sitting together simultaneously is historically uncommon for this company; whether that gap closes, widens, or persists is what the rest of this analysis examines.
How a quiet rare-disease company became a dealmaker
For most of its life, BioMarin was a specialist: a company that made medicines almost nobody needed, in the best possible sense. Its drugs treat conditions so rare that most doctors never see a case. That focus kept the business small but profitable in its own way, and largely ignored by the broader market. Then, between 2022 and today, revenue grew by more than half, a gene therapy was abandoned, a $4.8 billion acquisition closed, and a second deal was announced before the ink was dry on the first. The company that filed its Q2 2026 10-Q on August 6 looks materially different from the one that filed two years ago.
The contrast that opens this story is a simple one: revenue is growing briskly year over year, yet the stock sits below its recent highs. The math is improving; the mood, meaning what the market is currently willing to pay, has not kept pace. That tension is worth understanding.
The year’s arc: two acquisitions, one failure, one exit
The biggest event of the filing year was the completed purchase of Amicus Therapeutics on April 27, 2026, for roughly $4.8 billion in cash. That is more than BioMarin earned in total revenue across all of 2024. The deal brought two commercial drugs into the portfolio: GALAFOLD, which treats Fabry disease (a rare inherited condition that damages the heart and kidneys), and POMBILITI + OPFOLDA, which treats Pompe disease (a muscle-wasting disorder). Together, those two contributed meaningfully to quarterly revenue in a period when they weren’t in BioMarin’s books at all a year earlier.
At the same time, the company exited two programs. ROCTAVIAN, a gene therapy for hemophilia A that BioMarin had spent years and enormous sums developing, was voluntarily withdrawn from the market in early 2026. And BMN 401, a drug for a rare bone disease called ENPP1 deficiency, was discontinued after its Phase 3 trial failed to meet a key goal. Both exits are the kind of thing that stings in the short term and clarifies strategy in the long term: BioMarin is concentrating on what it can sell, not what it once hoped to prove.
Then, on August 18, BioMarin announced a deal to acquire Alesta Therapeutics for up to $490 million, adding ALE1, a potential first oral treatment for hypophosphatasia (a disease that weakens bones and teeth), to its clinical pipeline. The upfront cost is $275 million; the rest depends on whether the drug clears regulatory hurdles. For a company running at nearly a billion dollars in quarterly revenue, that is a manageable bet on a disease with no good oral option today.
What the revenue line actually says
The Q2 2026 filing shows total revenue of $989.7 million, up 20% from the same quarter a year earlier. VOXZOGO, BioMarin’s treatment for achondroplasia (the most common form of dwarfism), grew double digits and remains the company’s single largest product. PALYNZIQ, which treats a rare metabolic disorder called PKU, grew even faster. The Amicus drugs added a new layer on top of that organic growth.
Not everything moved in the right direction. VIMIZIM and ALDURAZYME, two older enzyme therapies, both declined in the quarter, though the filing attributes this to the timing of government orders rather than lost demand. That distinction matters: a lumpy government order is a timing problem; a lost customer is a structural one. The data doesn’t yet tell us which this is.
From a business-structure standpoint, the revenue base is now wider and more diversified than it was twelve months ago, which, in principle, reduces the degree to which any single drug’s stumble could affect the whole company’s top line.
The pipeline: what’s advancing, what’s next
BioMarin submitted a supplemental application to the FDA to expand VOXZOGO’s approved use to hypochondroplasia, a related bone-growth condition, after pivotal study results exceeded expectations as of May 20, 2026. The FDA also accepted a separate application for full approval of VOXZOGO in children with achondroplasia, with a decision date set for February 28, 2027. A next-generation version of the same mechanism, BMN 333, is enrolling in a Phase 2/3 study, with early data supporting a once-weekly dosing schedule that could be more convenient than the current daily injection.
Research and development spending rose sharply in the quarter, driven largely by integrating the Amicus pipeline. The BMN 401 discontinuation will free some of that spending for other programs, but the net direction is clearly toward more investment, not less.
Reading the numbers
- $989.7 million, Q2 2026 revenue. What it is: total sales for the three months ended June 30, 2026, per the 10-Q filed August 6. What it means here: BioMarin is now running at a pace of nearly $4 billion a year, up substantially from where it was four years ago. Everyday version: if a local hospital system billed $10 million a quarter four years ago and now bills $20 million, it has either gotten much better at what it does or bought a competitor, or both. BioMarin did both.
- 10.8% net margin, FY2025. What it is: of every dollar BioMarin collected in 2025, it kept about eleven cents as profit after all costs, per our data computed from the 10-K for fiscal year ended December 31, 2025. What it means here: that is down from 15% in FY2024, reflecting the cost of absorbing Amicus. Everyday version: a restaurant that earned $15 on every $100 in meals last year is now earning $11, because it just opened a second location and the new kitchen is still learning the menu.
- P/S ratio of 4.0, versus a decade median of 7.9. What it is: the price-to-sales ratio is the price the market puts on each dollar of annual revenue. At 4.0, BioMarin trades near the bottom of its own ten-year range, per our data. What it means here: the market is paying roughly half what it historically has for each dollar of BioMarin’s sales, even as those sales are growing faster than they have in years. Everyday version: a bakery that used to sell for eight times its annual sales is now on offer at four times, while it’s selling more bread than ever. That gap is either a bargain or a warning, and the data alone cannot tell us which.
- $4.8 billion, Amicus acquisition cost. What it is: the all-cash price paid on April 27, 2026, per the acquisition announcement. What it means here: BioMarin spent more than a full year of its prior revenue on a single deal. Everyday version: a household earning $60,000 a year taking on a $65,000 purchase. It can be worth it, but the debt load changes the math on everything else for years.
Sources
- BioMarin 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- BioMarin 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- BioMarin 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
- BioMarin press release: Amicus acquisition close, April 27, 2026
- BioMarin Q2 2026 financial and operating results press release
- StockTitan: BioMarin 10-Q filing summary and Alesta acquisition announcement
- BioMarin Q2 2026 earnings call transcript (Seeking Alpha)
